Bimzelx (Bimekizumab) is More Effective Than Cosentyx (Secukinumab) for Psoriatic Arthritis Treatment
Based on the most recent head-to-head comparative evidence, bimekizumab demonstrates superior efficacy to secukinumab for treating psoriatic arthritis, particularly in patients who have failed TNF inhibitors and for achieving deeper disease control (ACR70 and MDA responses).
Evidence Supporting Bimekizumab's Superior Efficacy
The 2024 matching-adjusted indirect comparison (MAIC) provides the strongest comparative evidence 1. At 52 weeks:
In Biologic-Naïve Patients:
- Bimekizumab showed significantly greater likelihood of ACR70 response compared to both secukinumab doses:
- vs. secukinumab 150 mg: odds ratio 2.39 (95% CI 1.26-4.53; p=0.008)
- vs. secukinumab 300 mg: odds ratio 2.03 (95% CI 1.11-3.72; p=0.021)
- For ACR20 and ACR50, responses were comparable between bimekizumab and secukinumab
In TNF Inhibitor-Inadequate Responders (TNFi-IR):
This is where bimekizumab's advantage is most pronounced 1:
- vs. secukinumab 150 mg, bimekizumab showed superior responses across all measures:
- ACR20: OR 3.50 (1.64-7.49; p=0.001)
- ACR50: OR 3.32 (1.41-7.80; p=0.006)
- ACR70: OR 2.95 (1.08-8.07; p=0.035)
- MDA: OR 3.52 (1.38-8.99; p=0.009)
- vs. secukinumab 300 mg, bimekizumab showed superior responses for:
- ACR50: OR 2.44 (1.06-5.65; p=0.037)
- MDA: OR 2.92 (1.20-7.09; p=0.018)
Guideline Context
Both medications are approved IL-17 inhibitors in the 2024 EULAR guidelines 2. However, the guidelines note that bimekizumab uniquely inhibits both IL-17A and IL-17F, while secukinumab only targets IL-17A 3, 2. This dual inhibition mechanism likely explains bimekizumab's enhanced efficacy.
The BE OPTIMAL and BE COMPLETE trials (both low risk of bias) demonstrated bimekizumab's robust efficacy 3, 4, 5:
- BE OPTIMAL (biologic-naïve): 44% achieved ACR50 at week 16 vs. 10% placebo (p<0.0001)
- BE COMPLETE (TNFi-IR): 43% achieved ACR50 at week 16 vs. 7% placebo (p<0.0001)
Clinical Decision Algorithm
Choose Bimekizumab over Secukinumab when:
- Patient has failed TNF inhibitors - This is the clearest indication, with 2-3.5× greater odds of response
- Goal is achieving minimal disease activity (MDA) - Bimekizumab shows consistent superiority for this stringent outcome
- Seeking deeper disease control (ACR70) - Even in biologic-naïve patients, bimekizumab outperforms
Secukinumab remains reasonable when:
- Patient is biologic-naïve and ACR20/50 response is the primary goal (comparable efficacy)
- Cost considerations are paramount (though this varies by healthcare system)
- Patient has contraindications to bimekizumab
Dosing Considerations
Per FDA labeling 6:
- Bimekizumab for PsA: 160 mg subcutaneously every 4 weeks
- If coexistent moderate-to-severe plaque psoriasis: Use 320 mg at weeks 0,4,8,12,16, then every 8 weeks
This differs from secukinumab's dosing and may influence practical treatment decisions.
Safety Profile
Both medications share similar safety profiles consistent with IL-17 inhibition 3, 4, 5. The most common adverse events include:
- Nasopharyngitis and upper respiratory infections
- Fungal infections (particularly oral candidiasis)
- No deaths reported in pivotal trials
Key caveat: Screen for tuberculosis and check liver enzymes before initiating bimekizumab 6. Complete age-appropriate vaccinations prior to treatment.
Long-Term Efficacy
Two-year data from BE OPTIMAL and BE COMPLETE demonstrate sustained efficacy of bimekizumab with maintained safety profile 7, supporting its use as a durable treatment option.
The model-based meta-analysis further supports bimekizumab's position, predicting median ACR50 response rates of 44% for bimekizumab 160 mg versus 28% for secukinumab 150 mg at week 16 in biologic-naïve patients 8.